CITALOPRAM
Pharmacotherapy
The University of Hong KongSmall moleculePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Pharmacotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cipralex The University of Hong Kong | Phase 2/3 | B |
Paliperidone Palmitate 3-Month Formulation The University of Hong Kong | Phase 2/3 | B |
Sertraline The University of Hong Kong | Phase 2/3 | B |
Same molecule, other indications
CITALOPRAM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →